Plain-English translation of NCT04590326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new immunotherapy medication called to see if it can help treat certain cancers, including ovarian, fallopian tube, peritoneal, and endometrial cancers. The medication works by training your immune system to recognize and attack cancer cells. Researchers will test the medication alone or combined with other approved immunotherapy drugs to find the safest dose and see how well it works.
Many women with advanced ovarian and endometrial cancers have limited treatment options, especially after their cancer has progressed despite previous chemotherapy and immunotherapy. This trial exists to explore whether this new medication could offer hope for patients whose cancers have become resistant to current treatments.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic regularly for infusions of the medication and monitoring appointments. Depending on which treatment group you join, you will receive the medication alone or in combination with other drugs, with visits occurring more frequently at first and then spaced out over time. The study will track your cancer through blood tests, scans, and physical exams to see how your body responds and to watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States